To assess the efficacy and safety of oral decernotinib ( VX-509 ; Vertex Pharmaceuticals ) monotherapy in a 12-week , randomized , double-blind , placebo-controlled , dose-ranging study of patients with rheumatoid arthritis ( RA ) .